DNA methylation and demethylation probed by small molecules

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1799, Issue 10-12, 2010, Pages 750-759

  Szyf, Moshe ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

5 azaC; Anticancer drug; DNA demethylation; DNA methylation; Epigenetics; MBD2; SAM; Small molecules

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; DNA BINDING PROTEIN; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HYDRALAZINE; METHYL CPG BINDING PROTEIN 2; PROCAINAMIDE; S ADENOSYLMETHIONINE; VALPROIC ACID; ZEBULARINE;

AUTOIMMUNE DISEASE; BREAST CANCER; CHROMATIN; CLINICAL TRIAL; DEMETHYLATION; DNA METHYLATION; GENE EXPRESSION; GENE SILENCING; HUMAN; KIDNEY CANCER; LIVER CANCER; LUPUS VULGARIS; MAXIMUM TOLERATED DOSE; METASTASIS; MITOSIS; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; TUMOR GENE; TUMOR SUPPRESSOR GENE;

ANIMALS; DNA METHYLATION; DNA MODIFICATION METHYLASES; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; HUMANS; MITOSIS; NEOPLASMS;

EID: 78649880974     PISSN: 18749399     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2010.09.002     Document Type: Review

References (126)

1. Razin A., Riggs A.D. DNA methylation and gene function. Science 1980, 210:604-610.
2. Razin A., Szyf M. DNA methylation patterns. Formation and function. Biochim. Biophys. Acta 1984, 782:331-342.
3. Razin A., Shemer R. DNA methylation in early development. Hum. Mol. Genet. 1995, 4:1751-1755.
4. Ramchandani S., Bhattacharya S.K., Cervoni N., Szyf M. DNA methylation is a reversible biological signal. Proc. Natl. Acad. Sci. USA 1999, 96:6107-6112.
5. Weaver I.C., Cervoni N., Champagne F.A., D'Alessio A.C., Sharma S., Seckl J.R., Dymov S., Szyf M., Meaney M.J. Epigenetic programming by maternal behavior. Nat. Neurosci. 2004, 7:847-854. (What's new for "DNA methylation" in PubMed.).
6. McGowan P.O., Sasaki A., D'Alessio A.C., Dymov S., Labonte B., Szyf M., Turecki G., Meaney M.J. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat. Neurosci. 2009, 12:342-348.
7. J. Feng, Y. Zhou, S.L. Campbell, T. Le, E. Li, J.D. Sweatt, A.J. Silva, G. Fan, Dnmt1 and Dnmt3a maintain DNA methylation and regulate synaptic function in adult forebrain neurons, Nat. Neurosci. 13 (2010) 423-430.
8. Levenson J.M., Roth T.L., Lubin F.D., Miller C.A., Huang I.C., Desai P., Malone L.M., Sweatt J.D. Evidence that DNA (cytosine-5) methyltransferase regulates synaptic plasticity in the hippocampus. J. Biol. Chem. 2006, 281:15763-15773.
9. Miller C.A., Campbell S.L., Sweatt J.D. DNA methylation and histone acetylation work in concert to regulate memory formation and synaptic plasticity. Neurobiol. Learn. Mem. 2008, 89:599-603.
10. Miller C.A., Sweatt J.D. Covalent modification of DNA regulates memory formation. Neuron 2007, 53:857-869.
11. Razin A., Cedar H. Distribution of 5-methylcytosine in chromatin. Proc. Natl. Acad. Sci. USA 1977, 74:2725-2728.
12. Rauch T.A., Wu X., Zhong X., Riggs A.D., Pfeifer G.P. A human B cell methylome at 100-base pair resolution. Proc. Natl. Acad. Sci. USA 2009, 106:671-678.
13. Comb M., Goodman H.M. CpG methylation inhibits proenkephalin gene expression and binding of the transcription factor AP-2. Nucleic Acids Res. 1990, 18:3975-3982.
14. Inamdar N.M., Ehrlich K.C., Ehrlich M. CpG methylation inhibits binding of several sequence-specific DNA-binding proteins from pea, wheat, soybean and cauliflower. Plant Mol. Biol. 1991, 17:111-123.
15. Nan X., Campoy F.J., Bird A. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 1997, 88:471-481.
16. Zhang Y., Ng H.H., Erdjument-Bromage H., Tempst P., Bird A., Reinberg D. Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev. 1999, 13:1924-1935.
17. Kuendgen A., Lubbert M. Current status of epigenetic treatment in myelodysplastic syndromes. Ann. Hematol. 2008, 87:601-611.
18. Venturelli S., Armeanu S., Pathil A., Hsieh C.J., Weiss T.S., Vonthein R., Wehrmann M., Gregor M., Lauer U.M., Bitzer M. Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma. Cancer 2007, 109:2132-2141.
19. Hellman A., Chess A. Gene body-specific methylation on the active X chromosome. Science 2007, 315:1141-1143.
20. Lister R., Pelizzola M., Dowen R.H., Hawkins R.D., Hon G., Tonti-Filippini J., Nery J.R., Lee L., Ye Z., Ngo Q.M., Edsall L., Antosiewicz-Bourget J., Stewart R., Ruotti V., Millar A.H., Thomson J.A., Ren B., Ecker J.R. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 2009, 462:315-322.
21. Gagnon-Kugler T., Langlois F., Stefanovsky V., Lessard F., Moss T. Loss of human ribosomal gene CpG methylation enhances cryptic RNA polymerase II transcription and disrupts ribosomal RNA processing. Mol. Cell 2009, 35:414-425.
22. Okano M., Xie S., Li E. Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases [letter]. Nat. Genet. 1998, 19:219-220.
23. Vilain A., Apiou F., Dutrillaux B., Malfoy B. Assignment of candidate DNA methyltransferase gene (DNMT2) to human chromosome band 10p15.1 by in situ hybridization. Cytogenet. Cell Genet. 1998, 82:120.
24. Rai K., Chidester S., Zavala C.V., Manos E.J., James S.R., Karpf A.R., Jones D.A., Cairns B.R. Dnmt2 functions in the cytoplasm to promote liver, brain, and retina development in zebrafish. Genes Dev. 2007, 21:261-266.
25. Goll M.G., Kirpekar F., Maggert K.A., Yoder J.A., Hsieh C.L., Zhang X., Golic K.G., Jacobsen S.E., Bestor T.H. Methylation of tRNAAsp by the DNA methyltransferase homolog Dnmt2. Science 2006, 311:395-398.
26. Bourc'his D., Xu G.L., Lin C.S., Bollman B., Bestor T.H. Dnmt3L and the establishment of maternal genomic imprints. Science 2001, 294:2536-2539.
27. Bourc'his D., Bestor T.H. Meiotic catastrophe and retrotransposon reactivation in male germ cells lacking Dnmt3L. Nature 2004, 431:96-99.
28. Li E., Bestor T.H., Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 1992, 69:915-926.
29. Chen T., Hevi S., Gay F., Tsujimoto N., He T., Zhang B., Ueda Y., Li E. Complete inactivation of DNMT1 leads to mitotic catastrophe in human cancer cells. Nat. Genet. 2007, 39:391-396.
30. Okano M., Bell D.W., Haber D.A., Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999, 99:247-257.
31. Bostick M., Kim J.K., Esteve P.O., Clark A., Pradhan S., Jacobsen S.E. UHRF1 plays a role in maintaining DNA methylation in mammalian cells. Science 2007, 317:1760-1764.
32. Szyf M., Eliasson L., Mann V., Klein G., Razin A. Cellular and viral DNA hypomethylation associated with induction of Epstein-Barr virus lytic cycle. Proc. Natl. Acad. Sci. USA 1985, 82:8090-8094.
33. Oswald J., Engemann S., Lane N., Mayer W., Olek A., Fundele R., Dean W., Reik W., Walter J. Active demethylation of the paternal genome in the mouse zygote. Curr. Biol. 2000, 10:475-478.
34. Lucarelli M., Fuso A., Strom R., Scarpa S. The dynamics of myogenin site-specific demethylation is strongly correlated with its expression and with muscle differentiation. J. Biol. Chem. 2001, 276:7500-7506.
35. Bruniquel D., Schwartz R.H. Selective, stable demethylation of the interleukin-2 gene enhances transcription by an active process. Nat. Immunol. 2003, 4:235-240.
36. Wilks A., Seldran M., Jost J.P. An estrogen-dependent demethylation at the 5' end of the chicken vitellogenin gene is independent of DNA synthesis. Nucleic Acids Res. 1984, 12:1163-1177.
37. Szyf M., Theberge J., Bozovic V. Ras induces a general DNA demethylation activity in mouse embryonal P19 cells. J. Biol. Chem. 1995, 270:12690-12696.
38. Mastronardi F.G., Noor A., Wood D.D., Paton T., Moscarello M.A. Peptidyl argininedeiminase 2 CpG island in multiple sclerosis white matter is hypomethylated. J. Neurosci. Res. 2007, 85:2006-2016.
39. Dong E., Nelson M., Grayson D.R., Costa E., Guidotti A. Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation. Proc. Natl. Acad. Sci. USA 2008, 105:13614-13619.
40. Jost J.P. Nuclear extracts of chicken embryos promote an active demethylation of DNA by excision repair of 5-methyldeoxycytidine. Proc. Natl. Acad. Sci. USA 1993, 90:4684-4688.
41. Razin A., Szyf M., Kafri T., Roll M., Giloh H., Scarpa S., Carotti D., Cantoni G.L. Replacement of 5-methylcytosine by cytosine: a possible mechanism for transient DNA demethylation during differentiation. Proc. Natl. Acad. Sci. USA 1986, 83:2827-2831.
42. Kangaspeska S., Stride B., Metivier R., Polycarpou-Schwarz M., Ibberson D., Carmouche R.P., Benes V., Gannon F., Reid G. Transient cyclical methylation of promoter DNA. Nature 2008, 452:112-115.
43. Shen J.C., Rideout W.M.d., Jones P.A. High frequency mutagenesis by a DNA methyltransferase. Cell 1992, 71:1073-1080.
44. Zingg J.M., Shen J.C., Jones P.A. Enzyme-mediated cytosine deamination by the bacterial methyltransferase M.MspI. Biochem. J. 1998, 332:223-230.
45. Barreto G., Schafer A., Marhold J., Stach D., Swaminathan S.K., Handa V., Doderlein G., Maltry N., Wu W., Lyko F., Niehrs C. Gadd45a promotes epigenetic gene activation by repair-mediated DNA demethylation. Nature 2007, 445:671-675.
46. Jin S.G., Guo C., Pfeifer G.P. GADD45A does not promote DNA demethylation. PLoS Genet. 2008, 4:e1000013.
47. Rai K., Huggins I.J., James S.R., Karpf A.R., Jones D.A., Cairns B.R. DNA demethylation in zebrafish involves the coupling of a deaminase, a glycosylase, and gadd45. Cell 2008, 135:1201-1212.
48. C. Popp, W. Dean, S. Feng, S.J. Cokus, S. Andrews, M. Pellegrini, S.E. Jacobsen, W. Reik, Genome-wide erasure of DNA methylation in mouse primordial germ cells is affected by AID deficiency, Nature 463 (2010) 1101-1105.
49. Fujita H., Fujii R., Aratani S., Amano T., Fukamizu A., Nakajima T. Antithetic effects of MBD2a on gene regulation. Mol. Cell. Biol. 2003, 23:2645-2657.
50. Angrisano T., Lembo F., Pero R., Natale F., Fusco A., Avvedimento V.E., Bruni C.B., Chiariotti L. TACC3 mediates the association of MBD2 with histone acetyltransferases and relieves transcriptional repression of methylated promoters. Nucleic Acids Res. 2006, 34:364-372.
51. Ng H.H., Zhang Y., Hendrich B., Johnson C.A., Turner B.M., Erdjument-Bromage H., Tempst P., Reinberg D., Bird A. MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex [see comments]. Nat. Genet. 1999, 23:58-61.
52. Wade P.A., Gegonne A., Jones P.L., Ballestar E., Aubry F., Wolffe A.P. Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation [see comments]. Nat. Genet. 1999, 23:62-66.
53. Detich N., Theberge J., Szyf M. Promoter-specific activation and demethylation by MBD2/demethylase. J. Biol. Chem. 2002, 277:35791-35794.
54. Hamm S., Just G., Lacoste N., Moitessier N., Szyf M., Mamer O. On the mechanism of demethylation of 5-methylcytosine in DNA. Bioorg. Med. Chem. Lett. 2008, 18:1046-1049.
55. Pelizzola M., Koga Y., Urban A.E., Krauthammer M., Weissman S., Halaban R., Molinaro A.M. MEDME: an experimental and analytical methodology for the estimation of DNA methylation levels based on microarray derived MeDIP-enrichment. Genome Res. 2008, 18:1652-1656.
56. S. Ito, A.C. D'Alessio, O.V. Taranova, K. Hong, L.C. Sowers, Y. Zhang, Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification, Nature 466 (2010) 1129-1133.
57. Grayson D.R., Jia X., Chen Y., Sharma R.P., Mitchell C.P., Guidotti A., Costa E. Reelin promoter hypermethylation in schizophrenia. Proc. Natl. Acad. Sci. USA 2005, 102:9341-9346.
58. Petronis A., Gottesman I.I., Kan P., Kennedy J.L., Basile V.S., Paterson A.D., Popendikyte V. Monozygotic twins exhibit numerous epigenetic differences: clues to twin discordance?. Schizophr. Bull. 2003, 29:169-178.
59. Veldic M., Guidotti A., Maloku E., Davis J.M., Costa E. In psychosis, cortical interneurons overexpress DNA-methyltransferase 1. Proc. Natl. Acad. Sci. USA 2005, 102:2152-2157.
60. Balada E., Ordi-Ros J., Serrano-Acedo S., Martinez-Lostao L., Rosa-Leyva M., Vilardell-Tarres M. Transcript levels of DNA methyltransferases DNMT1, DNMT3A and DNMT3B in CD4+ T cells from patients with systemic lupus erythematosus. Immunology 2008, 124:339-347.
61. Balada E., Ordi-Ros J., Serrano-Acedo S., Martinez-Lostao L., Vilardell-Tarres M. Transcript overexpression of the MBD2 and MBD4 genes in CD4+ T cells from systemic lupus erythematosus patients. J. Leukoc. Biol. 2007, 81:1609-1616.
62. Balada E., Ordi-Ros J., Vilardell-Tarres M. DNA methylation and systemic lupus erythematosus. Ann. NY Acad. Sci. 2007, 1108:127-136.
63. Yung R.L., Richardson B.C. Role of T cell DNA methylation in lupus syndromes. Lupus 1994, 3:487-491.
64. Gluckman P.D., Hanson M.A., Buklijas T., Low F.M., Beedle A.S. Epigenetic mechanisms that underpin metabolic and cardiovascular diseases. Nat. Rev. Endocrinol. 2009, 5:401-408.
65. Stenvinkel P., Karimi M., Johansson S., Axelsson J., Suliman M., Lindholm B., Heimburger O., Barany P., Alvestrand A., Nordfors L., Qureshi A.R., Ekstrom T.J., Schalling M. Impact of inflammation on epigenetic DNA methylation-a novel risk factor for cardiovascular disease?. J. Intern. Med. 2007, 261:488-499.
66. Ling C., Del Guerra S., Lupi R., Ronn T., Granhall C., Luthman H., Masiello P., Marchetti P., Groop L., Del Prato S. Epigenetic regulation of PPARGC1A in human type 2 diabetic islets and effect on insulin secretion. Diabetologia 2008, 51:615-622.
67. Maier S., Olek A. Diabetes: a candidate disease for efficient DNA methylation profiling. J. Nutr. 2002, 132:2440S-2443S.
68. Corwin E.J. The concept of epigenetics and its role in the development of cardiovascular disease: commentary on "new and emerging theories of cardiovascular disease". Biol. Res. Nurs. 2004, 6:11-16. (discussion 21-13).
69. Hanson M.A., Gluckman P.D. Developmental origins of health and disease: new insights. Basic Clin. Pharmacol. Toxicol. 2008, 102:90-93.
70. Szyf M. DNA methylation properties: consequences for pharmacology. Trends Pharmacol. Sci. 1994, 15:233-238.
71. Baylin S.B., Esteller M., Rountree M.R., Bachman K.E., Schuebel K., Herman J.G. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum. Mol. Genet. 2001, 10:687-692.
72. Issa J.P., Vertino P.M., Wu J., Sazawal S., Celano P., Nelkin B.D., Hamilton S.R., Baylin S.B. Increased cytosine DNA-methyltransferase activity during colon cancer progression. J. Natl. Cancer Inst. 1993, 85:1235-1240.
73. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 2002, 21:5400-5413.
74. Shteper P.J., Zcharia E., Ashhab Y., Peretz T., Vlodavsky I., Ben-Yehuda D. Role of promoter methylation in regulation of the mammalian heparanase gene. Oncogene 2003, 22:7737-7749.
75. Shukeir N., Pakneshan P., Chen G., Szyf M., Rabbani S.A. Alteration of the methylation status of tumor-promoting genes decreases prostate cancer cell invasiveness and tumorigenesis in vitro and in vivo. Cancer Res. 2006, 66:9202-9210.
76. Pakneshan P., Szyf M., Farias-Eisner R., Rabbani S.A. Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis. J. Biol. Chem. 2004, 279:31735-31744.
77. Szyf M., Knox D.J., Milutinovic S., Slack A.D., Araujo F.D. How does DNA methyltransferase cause oncogenic transformation?. Ann. NY Acad. Sci. 2000, 910:156-174. (discussion 175-157).
78. Milutinovic S., Knox J.D., Szyf M. DNA methyltransferase inhibition induces the transcription of the tumor suppressor p21(WAF1/CIP1/sdi1). J. Biol. Chem. 2000, 275:6353-6359.
79. Knox J.D., Araujo F.D., Bigey P., Slack A.D., Price G.B., Zannis-Hadjopoulos M., Szyf M. Inhibition of DNA methyltransferase inhibits DNA replication. J. Biol. Chem. 2000, 275:17986-17990.
80. Milutinovic S., Zhuang Q., Niveleau A., Szyf M. Epigenomic stress response. Knockdown of DNA methyltransferase 1 triggers an intra-S-phase arrest of DNA replication and induction of stress response genes. J. Biol. Chem. 2003, 278:14985-14995.
81. Unterberger A., Andrews S.D., Weaver I.C., Szyf M. DNA methyltransferase 1 knockdown activates a replication stress checkpoint. Mol. Cell. Biol. 2006, 26:7575-7586.
82. Szyf M. DNA methylation and demethylation as targets for anticancer therapy. Biochemistry (Mosc) 2005, 70:533-549.
83. Vire E., Brenner C., Deplus R., Blanchon L., Fraga M., Didelot C., Morey L., Van Eynde A., Bernard D., Vanderwinden J.M., Bollen M., Esteller M., Di Croce L., de Launoit Y., Fuks F. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006, 439:871-874.
84. Di Croce L., Raker V.A., Corsaro M., Fazi F., Fanelli M., Faretta M., Fuks F., Lo Coco F., Kouzarides T., Nervi C., Minucci S., Pelicci P.G. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 2002, 295:1079-1082.
85. Schlesinger Y., Straussman R., Keshet I., Farkash S., Hecht M., Zimmerman J., Eden E., Yakhini Z., Ben-Shushan E., Reubinoff B.E., Bergman Y., Simon I., Cedar H. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat. Genet. 2007, 39:232-236.
86. Wu J.C., Santi D.V. On the mechanism and inhibition of DNA cytosine methyltransferases. Prog. Clin. Biol. Res. 1985, 198:119-129.
87. Cheng J.C., Matsen C.B., Gonzales F.A., Ye W., Greer S., Marquez V.E., Jones P.A., Selker E.U. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J. Natl. Cancer Inst. 2003, 95:399-409.
88. Juttermann R., Li E., Jaenisch R. Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc. Natl. Acad. Sci. USA 1994, 91:11797-11801.
89. Ghoshal K., Datta J., Majumder S., Bai S., Kutay H., Motiwala T., Jacob S.T. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol. Cell. Biol. 2005, 25:4727-4741.
90. Brueckner B., Boy R.G., Siedlecki P., Musch T., Kliem H.C., Zielenkiewicz P., Suhai S., Wiessler M., Lyko F. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res. 2005, 65:6305-6311.
91. Metivier R., Gallais R., Tiffoche C., Le Peron C., Jurkowska R.Z., Carmouche R.P., Ibberson D., Barath P., Demay F., Reid G., Benes V., Jeltsch A., Gannon F., Salbert G. Cyclical DNA methylation of a transcriptionally active promoter. Nature 2008, 452:45-50.
92. Cornacchia E., Golbus J., Maybaum J., Strahler J., Hanash S., Richardson B. Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J. Immunol. 1988, 140:2197-2200.
93. Scheinbart L.S., Johnson M.A., Gross L.A., Edelstein S.R., Richardson B.C. Procainamide inhibits DNA methyltransferase in a human T cell line. J. Rheumatol. 1991, 18:530-534.
94. Lee B.H., Yegnasubramanian S., Lin X., Nelson W.G. Procainamide is a specific inhibitor of DNA methyltransferase 1. J. Biol. Chem. 2005, 280:40749-40756.
95. Singh N., Duenas-Gonzalez A., Lyko F., Medina-Franco J.L. Molecular modeling and molecular dynamics studies of hydralazine with human DNA methyltransferase 1. ChemMedChem 2009, 4:792-799.
96. Castellano S., Kuck D., Sala M., Novellino E., Lyko F., Sbardella G. Constrained analogues of procaine as novel small molecule inhibitors of DNA methyltransferase-1. J. Med. Chem. 2008, 51:2321-2325.
97. Deng C., Lu Q., Zhang Z., Rao T., Attwood J., Yung R., Richardson B. Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling. Arthritis Rheum. 2003, 48:746-756.
98. Detich N., Bovenzi V., Szyf M. Valproate induces replication-independent active DNA demethylation. J. Biol. Chem. 2003, 278:27586-27592.
99. Milutinovic S., D'Alessio A.C., Detich N., Szyf M. Valproate induces widespread epigenetic reprogramming which involves demethylation of specific genes. Carcinogenesis 2007, 28:560-571.
100. Szyf M. The dynamic epigenome and its implications in toxicology. Toxicol. Sci. 2007, 100:7-23.
101. Richardson B. DNA methylation and autoimmune disease. Clin. Immunol. 2003, 109:72-79.
102. Oki Y., Aoki E., Issa J.P. Decitabine-bedside to bench. Crit. Rev. Oncol. Hematol. 2007, 61:140-152.
103. Weiss A.J., Metter G.E., Nealon T.F., Keanan J.P., Ramirez G., Swaiminathan A., Fletcher W.S., Moss S.E., Manthei R.W. Phase II study of 5-azacytidine in solid tumors. Cancer Treat. Rep. 1977, 61:55-58.
104. Soriano A.O., Yang H., Faderl S., Estrov Z., Giles F., Ravandi F., Cortes J., Wierda W.G., Ouzounian S., Quezada A., Pierce S., Estey E.H., Issa J.P., Kantarjian H.M., Garcia-Manero G. Safety and clinical activity of the combination of 5-azacytidine, valproic acid and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007, 110:2302-2308.
105. Milutinovic S., Brown S.E., Zhuang Q., Szyf M. DNA methyltransferase 1 knock down induces gene expression by a mechanism independent of DNA methylation and histone deacetylation. J. Biol. Chem. 2004, 279:27915-27927.
106. Lemaire M., Chabot G.G., Raynal N.J., Momparler L.F., Hurtubise A., Bernstein M.L., Momparler R.L. Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer. BMC Cancer 2008, 8:128.
107. Davis A.J., Gelmon K.A., Siu L.L., Moore M.J., Britten C.D., Mistry N., Klamut H., D'Aloisio S., MacLean M., Wainman N., Ayers D., Firby P., Besterman J.M., Reid G.K., Eisenhauer E.A. Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks. Invest. New Drugs 2003, 21:85-97.
108. Winquist E., Knox J., Ayoub J.P., Wood L., Wainman N., Reid G.K., Pearce L., Shah A., Eisenhauer E. Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study. Invest. New Drugs 2006, 24:159-167.
109. Wilson V.L., Jones P.A. DNA methylation decreases in aging but not in immortal cells. Science 1983, 220:1055-1057.
110. Moore L.E., Pfeiffer R.M., Poscablo C., Real F.X., Kogevinas M., Silverman D., Garcia-Closas R., Chanock S., Tardon A., Serra C., Carrato A., Dosemeci M., Garcia-Closas M., Esteller M., Fraga M., Rothman N., Malats N. Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case-control study. Lancet Oncol. 2008, 9:359-366.
111. Sato N., Fukushima N., Matsubayashi H., Goggins M. Identification of maspin and S100P as novel hypomethylation targets in pancreatic cancer using global gene expression profiling. Oncogene 2003, 8:1531-1538.
112. Rauch T.A., Zhong X., Wu X., Wang M., Kernstine K.H., Wang Z., Riggs A.D., Pfeifer G.P. High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer. Proc. Natl. Acad. Sci. USA 2008, 105:252-257.
113. Chen R.Z., Pettersson U., Beard C., Jackson-Grusby L., Jaenisch R. DNA hypomethylation leads to elevated mutation rates. Nature 1998, 395:89-93.
114. Howard G., Eiges R., Gaudet F., Jaenisch R., Eden A. Activation and transposition of endogenous retroviral elements in hypomethylation induced tumors in mice. Oncogene 2007.
115. Gaudet F., Hodgson J.G., Eden A., Jackson-Grusby L., Dausman J., Gray J.W., Leonhardt H., Jaenisch R. Induction of tumors in mice by genomic hypomethylation. Science 2003, 300:489-492.
116. Ateq B., Unterberger A., Rabbani S.A., Szyf M. Pharmacological Inhibition of DNA Methylation Induces Proinvasive and Prometastatic Genes In Vitro and In Vivo. Neoplasia 2008, 10:1-13.
117. Szyf M., Pakneshan P., Rabbani S.A. DNA methylation and breast cancer. Biochem. Pharmacol. 2004, 68:1187-1197.
118. Pascale R.M., Simile M.M., De Miglio M.R., Feo F. Chemoprevention of hepatocarcinogenesis: S-adenosyl-l-methionine. Alcohol 2002, 27:193-198.
119. Detich N., Hamm S., Just G., Knox J.D., Szyf M. The methyl donor S-adenosylmethionine inhibits active demethylation of DNA: a candidate novel mechanism for the pharmacological effects of S-adenosylmethionine. J. Biol. Chem. 2003, 278:20812-20820.
120. Pascale R.M., Simile M.M., Satta G., Seddaiu M.A., Daino L., Pinna G., Vinci M.A., Gaspa L., Feo F. Comparative effects of l-methionine, S-adenosyl-l-methionine and 5'-methylthioadenosine on the growth of preneoplastic lesions and DNA methylation in rat liver during the early stages of hepatocarcinogenesis. Anticancer Res. 1991, 11:1617-1624.
121. Ara A.I., Xia M., Ramani K., Mato J.M., Lu S.C. S-adenosylmethionine inhibits lipopolysaccharide-induced gene expression via modulation of histone methylation. Hepatology 2008, 47:1655-1666.
122. Ng H.H., Zhang Y., Hendrich B., Johnson C.A., Turner B.M., Erdjument-Bromage H., Tempst P., Reinberg D., Bird A. MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex. Nat. Genet. 1999, 23:58-61.
123. Goel A., Mathupala S.P., Pedersen P.L. Glucose metabolism in cancer. evidence that demethylation events play a role in activating type II hexokinase gene expression. J. Biol. Chem. 2003, 278:15333-15340.
124. Campbell P.M., Bovenzi V., Szyf M. Methylated DNA-binding protein 2 antisense inhibitors suppress tumourigenesis of human cancer cell lines in vitro and in vivo. Carcinogenesis 2004, 25:499-507.
125. Slack A., Bovenzi V., Bigey P., Ivanov M.A., Ramchandani S., Bhattacharya S., tenOever B., Lamrihi B., Scherman D., Szyf M. Antisense MBD2 gene therapy inhibits tumorigenesis. J. Gene Med. 2002, 4:381-389.
126. Campbell P.M., Bovenzi V., Szyf M. Methylated DNA binding protein 2 antisense inhibitors suppress tumorigenesis of human cancer lines in vitro and in vivo. Carcinogenesis 2003, 25:499-507.